Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 1987-1994

  Schmid, Peter ^a   Pinder, Sarah E ^b   Wheatley, Duncan ^e   Macaskill, Jane ^f   Zammit, Charles ^g   Hu, Jennifer ^d   Price, Robert ^c   Bundred, Nigel ^h   Hadad, Sirwan ⁱ   Shia, Alice ^a   Sarker, Shah Jalal ^a   Lim, Louise ^a   Gazinska, Patrycja ^b   Woodman, Natalie ^b   Korbie, Darren ^j   Trau, Matt ^j,k   Mainwaring, Paul ^l   Gendreau, Steven ^m   Lackner, Mark R ^m   Derynck, Mika ^m   Wilson, Timothy R ^m   Butler, Hannah ^g   Earl, Gemma ^g   Parker, Peter ^b   Purushotham, Arnie ^b   Thompson, Alastair ⁿ   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e ROYAL CORNWALL HOSPITAL   (United Kingdom)

^f NINEWELLS HOSPITAL   (United Kingdom)

^g Worthing Hospital   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ Sheffield Bone Meta Multidisc Team   (United Kingdom)

^j Australian Institute for Bioengineering and Nanotechnology   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l Mater Centre   (Australia)

^m GENENTECH INC   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROGESTERONE RECEPTOR; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; INDAZOLE DERIVATIVE; NITRILE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; HUMANS; INDAZOLES; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; POSTMENOPAUSE; PREOPERATIVE CARE; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SULFONAMIDES; TRIAZOLES;

EID: 84971659136     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.9179     Document Type: Article

References (28)

1. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29:4452-4461, 2011
2. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
3. Stephens PJ, Tarpey PS, Davies H, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-404, 2012
4. Thorpe LM, Yuzugullu H, Zhao JJ: PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15: 7-24, 2015
5. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107:10208-10213, 2010
6. Sabine VS, Crozier C, Brookes CL, et al: Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32:2951-2958, 2014
7. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al: Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2- negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31, 2013 (suppl; abstr LBA509)
8. López-Knowles E, Segal CV, Gao Q, et al: Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res 16:R68, 2014
9. O'Brien C, Wallin JJ, Sampath D, et al: Predictive biomarkers of sensitivity to the phosphatidylinositol 39 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16:3670-3683, 2010
10. Miller TW, Rexer BN, Garrett JT, et al: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224, 2011
11. Ghayad SE, Vendrell JA, Ben Larbi S, et al: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126:545-562, 2010
12. Crowder RJ, Phommaly C, Tao Y, et al: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69:3955-3962, 2009
13. Boulay A, Rudloff J, Ye J, et al: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319-5328, 2005
14. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
15. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005
16. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
17. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
18. Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebocontrolled phase II randomised trial. Lancet Oncol 6:383-391, 2005
19. Hadad S, Iwamoto T, Jordan L, et al: Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794, 2011
20. Macaskill EJ, Bartlett JM, Sabine VS, et al: The mammalian target of rapamycin inhibitor everolimus (RAD001) in earlybreast cancer: Results of a pre-operative study. Breast Cancer Res Treat 128:725-734, 2011
21. Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 11:174-183, 2010
22. Maisonneuve P, Disalvatore D, Rotmensz N, et al: Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2- negative) intrinsic breast cancer subtypes. Breast Cancer Res 16:R65, 2014
23. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
24. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009
25. Loi S, Michiels S, Baselga J, et al: PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 8:e53292, 2013
26. Ellis MJ, Lin L, Crowder R, et al: Phosphatidylinositol-3-kinase a catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119:379-390, 2010
27. Treilleux I, Arnedos M, Cropet C, et al: Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study. J Clin Oncol 31, 2013 (suppl; abstr 510)
28. Krop I, Johnston S, Mayer IA, et al: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer-Part I results. 37th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2014 (abstr S2-02)